The number of shares short will continue to grow (I believe this is obvious based on Level II and the last two short reports). I personally don't believe there is much to stop the downward trend other than Fluticare and FDA approval. As far as the conference goes, I can't believe there will be any good news without Fluticare approval. The people who are there are most likely counting on the same thing and are certainly more savvy than any of us.
At the end of October, there could be enough shorting action to drive the stock below 0.20. I don't think the stock will reach 0.11 but who knows.
Nothing has changed my mind as to when the FDA approval may come (still end of Q1 JMO).
I don't believe in hype. I take a look at what is happening and what will happen in the near future.
As far as Innovus goes, I really don't expect any significant change upward until end of Q1 if Fluticare gets approval or into Q3 without Fluticare approval.